These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37429433)

  • 1. Psoriasis Severity, Health-Related Quality of Life, Work Productivity, and Activity Impairments Among Patients With Moderate to Severe Psoriasis Receiving Systemic Treatment: Real-World Data From Clinical Practice in Spain.
    Daudén E; Vidal D; Romero A; Bordel MT; Rivera R; Márquez J; Zamora E; Martinez L; Ocaña MJ; Vila C; Iribarren P; Corona N; Zulaica A
    Actas Dermosifiliogr; 2024 Jan; 115(1):1-9. PubMed ID: 37429433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psoriasis Severity, Health-Related Quality of Life, Work Productivity, and Activity Impairments Among Patients With Moderate to Severe Psoriasis Receiving Systemic Treatment: Real-World Data From Clinical Practice in Spain.
    Daudén E; Vidal D; Romero A; Bordel MT; Rivera R; Márquez J; Zamora E; Martinez L; Ocaña MJ; Vila C; Iribarren P; Corona N; Zulaica A
    Actas Dermosifiliogr; 2024 Jan; 115(1):T1-T9. PubMed ID: 37923068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease severity, treatment patterns, and quality of life in patients with moderate-to-severe psoriasis routinely managed with systemic treatment: results of the CRYSTAL observational study in Central and Eastern European countries.
    Raam L; Hartmane I; Valiukevičienė S; Karamova AE; Telegdy E; Botev I; Marina D; Rubant S; Albuquerque T; Constantin MM
    Front Immunol; 2024; 15():1410540. PubMed ID: 38846952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of active and stable psoriasis on health-related quality of life: the PSO-LIFE study.
    Daudén E; Herrera E; Puig L; Sánchez-Carazo JL; Toribio J; Perulero N
    Actas Dermosifiliogr; 2013 Oct; 104(8):685-93. PubMed ID: 23958428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study.
    Daudén E; Pujol RM; Sánchez-Carazo JL; Toribio J; Vanaclocha F; Puig L; Yébenes M; Sabater E; Casado MA; Caloto MT; Aragón B;
    Actas Dermosifiliogr; 2013 Nov; 104(9):807-14. PubMed ID: 23827342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals.
    Norlin JM; Nilsson K; Persson U; Schmitt-Egenolf M
    Br J Dermatol; 2020 Apr; 182(4):965-973. PubMed ID: 31325318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice.
    Costanzo A; Llamas-Velasco M; Fabbrocini G; Cuccia A; Rivera-Diaz R; Gaarn Du Jardin K; Kasujee I; Puig L; Carrascosa JM
    J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):2004-2015. PubMed ID: 37246505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.
    Imafuku S; Kanai Y; Murotani K; Nomura T; Ito K; Ohata C; Yamazaki F; Miyagi T; Takahashi H; Okubo Y; Saeki H; Honma M; Tada Y; Mabuchi T; Higashiyama M; Kobayashi S; Hashimoto Y; Seishima M; Kakuma T
    J Dermatol Sci; 2021 Mar; 101(3):185-193. PubMed ID: 33495058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).
    Lacour JP; Bewley A; Hammond E; Hansen JB; Horne L; Paul C; Reich K; Seneschal J; De Simone C; Sohrt A; Augustin M; Pellacani G
    Dermatol Ther (Heidelb); 2020 Oct; 10(5):1099-1109. PubMed ID: 32761560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.
    Gooderham M; Pinter A; Ferris LK; Warren RB; Zhan T; Zeng J; Soliman AM; Kaufmann C; Kaplan B; Photowala H; Strober B
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):855-865. PubMed ID: 35174556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between clinical characteristics including presence of exposed lesions and health-related quality of life (HRQoL) in patients with psoriasis: analysis from the nationwide epidemiologic study for psoriasis in Korea (EPI-PSODE study).
    Youn SW; Lee JH; Yu DY; Kim Y; Kim BS; Seo SJ; Choe YB; Yun SK; Park J; Kim NI; Choi CW; Youn JI; Lee SJ; Lee MG; Kim KJ; Park CJ; Ro YS; Song HJ; Shin BS; Ahn SK; Lee JY; Won YH; Jang MS; Kim KH; Kim MH; Kim TY; Choi JH
    J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1499-1506. PubMed ID: 29430733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
    Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis.
    Stull DE; Griffiths CEM; Gilloteau I; Zhao Y; Guana A; Finlay AY; Sherif B; Houghton K; Puig L
    Br J Dermatol; 2018 Jun; 178(6):1297-1307. PubMed ID: 29355896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life.
    Gerdes S; Körber A; Biermann M; Karnthaler C; Reinhardt M
    J Dermatolog Treat; 2020 Aug; 31(5):470-475. PubMed ID: 32202943
    [No Abstract]   [Full Text] [Related]  

  • 15. Work productivity in real-life employed patients with plaque psoriasis: Results from the ProLOGUE study.
    Saeki H; Kanai Y; Murotani K; Ito K; Miyagi T; Takahashi H; Tada Y; Higashiyama M; Hashimoto Y; Kitabayashi H; Imafuku S
    J Dermatol; 2022 Oct; 49(10):970-978. PubMed ID: 35856276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of CoQ10 Administration to Psoriatic Iraqi Patients on Biological Therapy Upon Severity Index (PASI) and Quality of Life Index (DLQI) Before and After Therapy.
    Al-Oudah GA; Sahib AS; Al-Hattab MK; Al-Ameedee AA
    J Popul Ther Clin Pharmacol; 2022; 29(2):e52-e60. PubMed ID: 35848197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary.
    Herédi E; Rencz F; Balogh O; Gulácsi L; Herszényi K; Holló P; Jókai H; Kárpáti S; Péntek M; Remenyik É; Szegedi A; Brodszky V
    Eur J Health Econ; 2014 May; 15 Suppl 1():S111-9. PubMed ID: 24832842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psoriasis: correlation between severity index (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treatment.
    Silva MF; Fortes MR; Miot LD; Marques SA
    An Bras Dermatol; 2013; 88(5):760-3. PubMed ID: 24173182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of Life Benefit and Clinical Predictors of Complete Skin Clearance in Psoriasis: A Multicenter, Prospective, Real-World Study.
    Jiang Y; Li Y; Huang D; Zhong X; Yu Q; Liang Y; Dang L; Lv C; Lin B; Zhang F; Liang Y; Lu J; Shi Y
    Dermatology; 2023; 239(5):802-810. PubMed ID: 37311426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
    J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.